The choice to delay deciding whether or not to authorize Moderna’s COVID-19 vaccine for children has merit because of concerns about post-vaccination heart inflammation, experts said.
U.S. drug regulators recently opted not to decide right now on authorization for Moderna’s shot for kids between 12 and 17, according to Moderna, which is also delaying plans to file for authorization for its jab for kids as young as 6. The company said the Food and Drug Administration (FDA) is investigating post-vaccination myocarditis among youth.
